Abstract
Objective. The purpose of our study was to determine the relationship between the magnetic resonance (MR) parameters
of the heart and the most frequent cardiac arrhythmias in patients with hypertrophic cardiomyopathy (HCM).
Material and methods.We performed 56 cardiac magnetic resonance studies on 3T Philips Achieva ans 1.5 T Siemens
of the patients with HCM in the age 45±12.36. Male – 57% (n=32). We've got 66% patients with cardiac arrhythmias
by ECG-data: ventricular tachycardia (35.7%), atrioventricular (AV) block (8.9%), and atrial fibrillation (AF)
(21.4%), including paroxismal type (75%), permanent (16.6%), and persist (8.4%). Observation period during
9 years.
Results. In dependence on arrhythmia type before the surgical intervention we've divided patients into 4 groups. The
1st one patients with HCM without arrhythmias (n=19), the IId –HCM and AF (n=12), the IIId – HCM and VT
(n=20), the IVth HCM and AV-block (n=5). 40 (71.4%) patients underwent surgical correction of HCM, 17.5%,
(n=7) of them interventional (majority from II group 71%, n=5). The end diastolic volume (EDV) LV mean was
124.55±31.1 ml and EDV RV 91.93±31.9 ml, LV stroke volume (SV) 95.6±25.02 ml, RV SV – 59.13±21.67 ml,
LV ejection fraction (EF) 79.29±15.53%, RV (EF) 62.95±10.8%, LV myocardial mass 210.1±70.3 g. We've got the
minimal LV EDV value in the II group (115.3±20.8 ml), the maximal – in the I one (131.3±24.1 ml), LV EF the
maximal value in II group (87±13.5%), the minimal in IV group (70.4±4.2%). The maximal value of myocardial
mass we obtained in III group (228.5±59.5 g) and the highest % of myocardial fibrosis in II group (11±4.9%), the
most frequent location of fibrosis in the inferior septal LV wall according to AHA-classification. In the II group we've
got the maximal left atrium (LA) volume size. We obtained the MAPSE и TAPSE decrease in the II group
(4.9±1.7 mm, p<0.0001). The increase of epicardial fat in 41% (n=23), patients. And majority were from the
III group (50%, n=10).
Conclusion. Analysis of MRI markers indicates an important role in association with various arrhythmias in patients
with HCM. Changes in the functional parameters of the LV and RV, and the volumetric parameters of the LA depend
on the presence of arrhythmias.
References
- Thom T., Haase N., Rosamond W., Howard V.J.,
Rumsfeld J., Manolio T. et al. Heart disease and stroke
statistics – 2006 update: a report from the American
Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation. 2006; 113 (6):
e85–151. DOI: 10.1161/CIRCULATIONAHA.105.171600
- Lee R., McCarthy P.M., Wang E.C., Vaduganathan M.,
Kruse J., Malaisrie S.C. et al. Midterm survival in
patients treated for atrial fibrillation: a propensitymatched
comparison to patients without a history of atrial
fibrillation. J. Thorac. Cardiovasc. Surg. 2012; 143 (6):
1341–51. DOI: 10.1016/j.jtcvs.2012.02.006
- Bockeria L.A., Shengeliya L.D. Treatment of atrial fibrillation.
Part I. Long way to the gold standart. Annaly
Aritmologii (Annals of Arrhythmology). 2014; 11 (2):
64–76 (in Russ.). DOI: 10.15275/annaritmol.2014.2.1
- Cao C., Gupta S., Chandrakumar D., Nienaber T.A.,
Indraratna P., Ang S.C. et al. A meta-analysis of minimally
invasive versus conventional mitral valve repair for
patients with degenerative mitral disease. Ann.
Cardiothorac. Surg. 2013; 2 (6): 693–703. DOI:
10.3978/j.issn.2225-319X.2013.11.08
- Shmyrev V.A., Bogachev-Prokof'ev A.V., Lomivorotov
V.V., Ponomarev D.N., Perovskiy P.P. Minimally
invasive mitral valve surgery. An anesthesiologist's viewpoint.
Patologiya Krovoobrashcheniya i Kardiokhirurgiya
(Circulation Pathology and Cardiac Surgery). 2013; 17 (4):
11–4 (in Russ.). DOI: 10.21688/1681-3472-2013-4-11-14
- Gillinov A.M., Gelijns A.C., Parides M.K., DeRose J.J.
Jr., Moskowitz A.J., Voisine P. et al. Surgical ablation of
atrial fibrillation during mitral-valve surgery. N. Engl. J.
Med. 2015; 372 (15): 1399–409. DOI: 10.1056/NEJMoa1500528
- Robertson J.O., Saint L.L., Leidenfrost J.E., Damiano
R.J. Jr. Illustrated techniques for performing the Cox-
Maze IV procedure through a right mini-thoracotomy.
Ann. Cardiothorac. Surg. 2014; 3 (1): 105–16. DOI:
10.3978/j.issn.2225- 319X.2013.12.11
- Weimar T., Bailey M.S., Watanabe Y., Marin D.,
Maniar H.S., Schuessler R.B. et al. The Cox-maze IV
procedure for lone atrial fibrillation: a single center experience
in 100 consecutive patients. J. Interv. Card.
Electrophysiol. 2011; 31 (1): 47–54. DOI:
10.1007/s10840-011-9547-3
- Adabag A.S., Casey S.A., Kuskowski M.A. Spectrum and
prognostic significance of arrhythmias on ambulatory
Holter electrocardiogram in hypertrophic cardiomyopathy.
J. Am. Coll. Cardiol. 2005; 45: 697–704. DOI:
10.1016/j.accreview.2005.05.070
- Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A.,
Fifer M.A., Link M.S. et al. 2011 ACCF/AHA
Guideline for the diagnosis and treatment of hypertrophic
cardiomyopathy: A report of the American
College of Cardiology Foundation/American Heart
Association task force on practice guidelines.
Circulation. 2011; 124: 783–831. DOI: 10.1161/cir.0b013e318223e2bd
- Gu S., Liu Z., Liu Z. Prevalence and related factors of
arrhythmias in patients with hypertrophic cardiomyopathy.
Heart. 2012; 98 (Suppl. 2): E248-E249. DOI:
10.1136/heartjnl-2012-302920q.5
- Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M.,
Cecchi F., Charron Ph. et al. 2014 ESC Guidelines on
diagnosis and management of hypertrophic cardiomyopathy.
Eur. Heart J. 2014; 35 (39): 2733–79. DOI:
10.1093/eurheartj/ehu284
- Guttmann O.P., Rahman M. Sh., O'Mahony C.,
Anastasakis A., Elliott P.M. Atrial fibrillation and thromboembolism
in patients with hypertrophic cardiomyopathy
systematic review. Heart. 2013; 10: 276–304. DOI:
10.1136/heartjnl-2013-304276
- Dariy O.Yu., Aleksandrova S.A., Malenkov D.A.,
Bereznitskiy V.S., Yurpol'skaya L.A., Makarenko V.N. et
al. Magnetic-resonance myocardium mapping in hypertrophic
cardiomyopathy associated with atrial fibrillation.
Creative Cardiology. 2018; 12 (4): 328–40 (in Russ).
DOI: 10.24022/1997-3187-2018-12-4-328-340.
- O'Mahony C., Jichi F., Pavlou M., Monserrat L.,
Anastasakis A., Rapezzi C. et al. A novel clinical risk prediction
model for sudden cardiac death in hypertrophic
cardiomyopathy (HCM Risk-SCD). Eur. Heart J. 2014;
35 (30): 2010–20. DOI: 10.1093/eurheartj/eht439
- Choudhury L., Mahrholdt H., Wagner A. Myocardial
scarring in asymptomatic or mildly symptomatic patients
with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.
2002; 40 (21): 56e64. DOI: 10.1016/s1062-1458(03)00059-x
- Bockeria L.A., Tetvadze I.V., Malenkov D.A., Sanakoev
M.K. Combined septal myectomy from the right ventricle
and epicardial modification of cryo-maze procedure.
Annaly Aritmologii (Annals of Aritmology). 2013;
10 (2): 64–8 (in Russ.). DOI: 10.15275/annaritmol.2013.2.1
- Ismail T.F., Jabbour A., Gulati A., Mallorie A., Raza S.,
Cowling T.E. et al. Role of late gadolinium enhancement
cardiovascular magnetic resonance in the risk stratification
of hypertrophic cardiomyopathy. Heart. 2014; 100:
1851–8. DOI: 10.1136/heartjnl-2013-305471
- Ganau A., Devereux R.B., Roman M.J., de Simone G.,
Pickering Th.G., Saba P.S. et al. Patterns of left ventricular
hypetrophy and geometric remodeling in essential
hypertension. J. Am. Coll. Cardiol. 1992; 19: 1550–8.
DOI: 10.1016/0735-1097(92)90617-v
- Bockeria L.A., Berseneva M.I., Malenkov D.A.
Arrithmogenic complications of hypertrophic cardiomiopathy.
Annaly Aritmologii (Annals of Aritmology).
2010; 7 (3): 62–9 (in Russ.). DOI: 10.15275/annaritmol.2016.4.4
- Green J.J., Berger J.S., Kramer C.M., Salerno M.
Prognostic value of late gadolinium enhancement in clinical
outcomes for hypertrophic cardiomyopathy. J. Am.
Coll. Cardiol. Img. 2012; 5: 370–7. DOI: 10.1016/j.jcmg.2011.11.021
- Fujita T., Konno T., Yokawa J., Masuta E., Nagata Y.
et.al. Increased extent of myocardial fibrosis in genotyped
hypertrophic cardiomyopathy with ventricular
tachyarrhythmias. Cardiol. J. 2015; 66: 63–8. DOI:
10.1016/j.jjcc.2014.10.002
- Bockeria L.A., Bockeria O.L., Berseneva M.I.
Assessment of the left ventricle remodeling. Guidelines.
Moscow; 2009 (in Russ).
- Olivotto I., Cecchi F., Casey S.A., Dolara A., Traverse J.H.,
Maron B.J. Impact of atrial fibrillation on the clinical
course of hypertrophic cardiomyopathy. Circulation. 2001;
104: 2517–24. DOI: 10.1161/hc4601.097997
- Doesch Ch., Lossnitzer D., Rudic B., Tueluemen E.,
Budjan J., Haubenreisser H. et al. Right ventricular and
right atrial involvement can predict atrial fibrillation in
patients with hypertrophic cardiomyopathy? Int. J. Med.
Sci. 2016; 13 (1): 1–7. DOI: 10.7150/ijms.13530
- Bockeria L.A. Hypertrophic obstructive cardiomyopathy.
Annals of Surgery. 2013; 5: 5–14 (in Russ.) DOI:
10.15690/vramn.v67i5.263.
About the authors
- Ol'ga Yu. Dariy, Radiologist, orcid.org/0000-0003-0140-8166
-
Svetlana A. Aleksandrova, Cand. Med. Sc., Senior Researcher, orcid.org/0000-0002-7795-9709
-
Dmitriy A. Malenkov, Junior Researcher, orcid.org/0000-0003-4656-0209
-
Lyudmila A. Yurpol'skaya, Dr. Med. Sc., Leading Researcher;
-
Anastasiya V. Kabachkova, Cand. Biol. Sc., Associate Professor of the Faculty of Physical Culture;
-
Vladimir N. Makarenko, Dr. Med. Sc., Professor, Head of the Department, orcid.org/0000-0002-8700-7592
-
Leo A. Bockeria, Academician of Russian Academy of Sciences, Director, orcid.org/0000-0002-6180-2619
